Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Pluri Biotech Ltd. has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 5 distinct examiners across 4 distinct art units. This distribution shows that each pending matter is being handled by a different individual, with a slight concentration of art units relative to the number of examiners.
Karen A Canella is the busiest examiner for this portfolio, currently overseeing 1 pending office action. With 5 total pending actions and 5 distinct examiners, the workload is perfectly distributed across the identified individuals. The busiest examiner pending count of 1 confirms that no examiner is currently burdened with multiple cases for this company.
The 4 distinct art units indicate that the company's biotechnological interests are spread across several specialized examination groups. Practitioners should expect a variety of perspectives, as 5 distinct examiners are providing feedback on the 5 pending office actions. This breadth of involvement across 4 art units suggests that the company's intellectual property covers multiple distinct facets of the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 2 (40%) |
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CANELLA, KAREN A | 1 | 62.2% | +32.8% |
| ABEYRATNE-PERERA, HASHANTHI KOMITIGE | 1 | 0.0% | +0.0% |
| JOHNSON, KARA D | 1 | 69.5% | +24.6% |
| HASSAN, LIBAN M | 1 | 50.7% | +31.1% |
| SCHUBERG, LAURA J | 1 | 23.6% | +37.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17693457 | Methods And Compositions For Aesthetic And Cosmetic Treatment And Stimulating Hair Growth | JOHNSON, KARA D | 19d overdue |
| 18689276 | PLACENTAL CELL TREATMENT FOR CRITICAL LIMB ISCHEMIA PATIENT SUBPOPULATIONS | ABEYRATNE-PERERA, HASHANTHI KOMITIGE | — |
| 17047411 | METHODS AND COMPOSITIONS FOR FORMULATING AND DISPENSING PHARMACEUTICAL FORMULATIONS | SCHUBERG, LAURA J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17693457 | Methods And Compositions For Aesthetic And Cosmetic Treatment And Stimulating Hair Growth | JOHNSON, KARA D | 19d overdue |
| 19333338 | GENETICALLY ENGINEERED PLACENTAL MUCOSALASSOCIATED INVARIANT T (MAIT) CELLS AND USES THEREOF | CANELLA, KAREN A | — |
| 17276245 | Modular Bioreactor | HASSAN, LIBAN M | — |
| 17047411 | METHODS AND COMPOSITIONS FOR FORMULATING AND DISPENSING PHARMACEUTICAL FORMULATIONS | SCHUBERG, LAURA J | — |
| Art Unit | Apps |
|---|---|
| 1632 | 2 |
| 1643 | 1 |
| 1799 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19333338 | GENETICALLY ENGINEERED PLACENTAL MUCOSALASSOCIATED INVARIANT T (MAIT) CELLS AND USES THEREOF | CANELLA, KAREN A | 1643 | §112 | Final Rejection | — | Pending | Sep 18, 2025 |
| 18689276 | PLACENTAL CELL TREATMENT FOR CRITICAL LIMB ISCHEMIA PATIENT SUBPOPULATIONS | ABEYRATNE-PERERA, HASHANTHI KOMITIGE | 1632 | §101§102§103 | Non-Final OA | — | Pending | Mar 05, 2024 |
| 17693457 | Methods And Compositions For Aesthetic And Cosmetic Treatment And Stimulating Hair Growth | JOHNSON, KARA D | 1632 | §103§112 | Non-Final OA | 19d overdue | Pending | Mar 14, 2022 |
| 17276245 | Modular Bioreactor | HASSAN, LIBAN M | 1799 | §103 | Non-Final OA | — | Pending | Mar 15, 2021 |
| 17047411 | METHODS AND COMPOSITIONS FOR FORMULATING AND DISPENSING PHARMACEUTICAL FORMULATIONS | SCHUBERG, LAURA J | 1631 | §103 | Final Rejection | — | Pending | Oct 14, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial